Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Id-1 gene and gene products as therapeutic targets for treatment of breast cancer and other types of carcinoma

Patent ·
OSTI ID:1150642
A method for treatment of breast cancer and other types of cancer. The method comprises targeting and modulating Id-1 gene expression, if any, for the Id-1 gene, or gene products in breast or other epithelial cancers in a patient by delivering products that modulate Id-1 gene expression. When expressed, Id-1 gene is a prognostic indicator that cancer cells are invasive and metastatic.
Research Organization:
LBNL (Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States))
Sponsoring Organization:
USDOE
Assignee:
California Pacific Medical Center Research Institute (San Francisco, CA); The Regents of the University of California (Oakland, CA)
Patent Number(s):
8,809291
Application Number:
13/252,148
OSTI ID:
1150642
Country of Publication:
United States
Language:
English

References (3)

The helix-loop-helix transcription factor, Id-1, is overexpressed in medullary thyroid cancer journal December 2000
Id-1 and Id-2 Are Overexpressed in Pancreatic Cancer and in Dysplastic Lesions in Chronic Pancreatitis journal September 1999
A Novel Pathway for Mammary Epithelial Cell Invasion Induced by the Helix-Loop-Helix Protein Id-1 journal August 1998